Vietnam's vaccine market is entering a new phase of sustained growth as the country expands immunisation programmes, strengthens domestic vaccine manufacturing and increases investment in preventive healthcare. Rising demand for both paediatric and adult vaccines, together with government initiatives to improve vaccine access, is creating significant opportunities across the life sciences sector.
According to IMARC Group, Vietnam's vaccine market reached US$904.5 million in 2025 and is projected to grow to US$1.52 billion by 2034. The market is being driven by increasing awareness of immunisation, expanding vaccination coverage and continued advances in vaccine technologies.
Vaccines remain one of the most effective public health interventions, protecting against a wide range of infectious diseases while reducing healthcare costs and improving population health. Vietnam's market encompasses:
- Childhood immunisation programmes
- Adult vaccination
- Travel vaccines
- Seasonal influenza vaccines
- Human papillomavirus (HPV) vaccines
- Hepatitis vaccines
- Japanese encephalitis vaccines
- Dengue vaccines
- Pneumococcal vaccines
- Emerging therapeutic vaccines
Several structural trends are accelerating market growth:
- Expansion of the National Expanded Programme on Immunization (EPI).
- Growing public awareness of preventive healthcare.
- Increasing demand for adult and travel vaccinations.
- Rising incidence of vaccine-preventable infectious diseases, including dengue and hand, foot and mouth disease.
- Introduction of innovative technologies such as mRNA and recombinant vaccines.
- Expansion of private vaccination centres.
- Greater investment in domestic vaccine research, development and manufacturing.
One of the most significant developments is Vietnam's increasing focus on local vaccine production. In 2025, Sanofi and Vietnam Vaccine JSC (VNVC) launched construction of a vaccine manufacturing facility in Long An Province with an initial investment of approximately US$77 million.
The facility is expected to produce up to 100 million vaccine doses annually from 2027, strengthening Vietnam's domestic manufacturing capability while supporting exports to international markets.
Innovation is reshaping the vaccine landscape worldwide. Beyond traditional inactivated and live-attenuated vaccines, the market is increasingly adopting:
- mRNA vaccine platforms
- Recombinant protein vaccines
- Viral vector vaccines
- Conjugate vaccines
- Therapeutic cancer vaccines
- Personalised immunotherapies
These next-generation technologies are enabling faster vaccine development, improved efficacy and more rapid responses to emerging infectious diseases. At the same time, advances in needle-free delivery systems, nasal vaccines and microneedle patches are improving patient experience and supporting higher vaccination uptake.
Vietnam's vaccine sector also benefits from a favourable healthcare environment. Rising healthcare expenditure, a growing middle class and increasing investment in biotechnology are encouraging broader adoption of premium vaccines outside the national immunisation programme. Demand is particularly strong for HPV, pneumococcal, influenza, shingles and combination vaccines, reflecting changing demographics and increasing awareness of preventive healthcare.
Leading manufacturers including Sanofi, GSK, Pfizer, Merck & Co. (MSD), Moderna, BioNTech, AstraZeneca, CSL Seqirus, Takeda, Serum Institute of India, alongside Vietnamese manufacturers such as VNVC, VABIOTECH, POLYVAC and the Institute of Vaccines and Medical Biologicals (IVAC), continue to expand investment in vaccine development, manufacturing and distribution.
As Vietnam continues to strengthen healthcare resilience and expand access to modern immunisation programmes, vaccines are expected to remain one of the country's most important public health priorities. For vaccine manufacturers, bioprocessing companies, cold-chain logistics providers, fill-finish specialists, packaging suppliers and pharmaceutical equipment manufacturers, Vietnam represents one of Southeast Asia's most attractive long-term growth markets.
